Monday, November 16, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Press releaseGlobeNewswire· March 19, 2026

Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update

View original at globenewswire.com
Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update ─Completed Successful FDA End-of-Phase 2 Meeting Following Positive Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis (PSC)─ ─Achieved Alignment with FDA on Clear and Efficient Pathw…
Opening lines of the source · GlobeNewswire · short snapshot: read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Phase 2 SPRING trial data viewed by many experts as the strongest to date in PSC

    60% confidence
  • Nebokitug may halt or slow disease progression and improve clinical outcomes

    60% confidence
  • Using a clinical event-driven endpoint helps de-risk the Phase 3 program

    60% confidence
  • Evaluating additional therapeutic indications where nebokitug has generated robust preclinical efficacy signals

    60% confidence
  • Current cash runway expected to take company through end of Q1 2027

    60% confidence
  • Nebokitug has potential to become first disease-modifying treatment for PSC

    60% confidence
  • Discussions with potential strategic partners continue to advance

    60% confidence
  • 2025 was a critical year for Chemomab and the nebokitug program

    60% confidence
  • Key publications have linked PSC-related biomarker improvements in SPRING trial with reductions in clinical events

    60% confidence

Cited in these Via News reports

Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update: Source | Via News | finance.via.news